Monte Rosa Therapeutics, Inc. GLUE Increase Decrease In Collaboration Receivable

Other financials

Revenue$4.2M-95.0%

Operating income-$50.0M-214%

Net income-$44.5M-195%

EPS (diluted)-$0.45-179%

Cash & equivalents$159.9M+104%

Total debt$39.1M-6.7%

Total equity$521.9M+89.7%

Total assets$736.4M+87.3%

Operating cash flow-$37.4M+17.9%

CapEx$1.9M+17.7%

Free cash flow-$39.2M+16.7%

Market cap$1.76B+361%

Enterprise value$1.64B+381%

P/S41×+38.6×

Operating margin-345.2%—

Net margin-302.6%—

FCF margin-45.8%-64.9pp

Return on equity-32.6%—

Debt / equity0.1×-0.1×

Current ratio9.5×+3.9×

Reported directly by Monte Rosa Therapeutics, Inc. in its filing.

Tagged under the XBRL concept glue:IncreaseDecreaseInCollaborationReceivable.

The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Monte Rosa Therapeutics, Inc.'s increase decrease in collaboration receivable?: Monte Rosa Therapeutics, Inc. (GLUE) reported increase decrease in collaboration receivable of -$7M in Q1 2026.